KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLong-Term Debt IssuancesR&D In ProcessReceivables - NetReceivables - Other
Ratios

Eli Lilly (LLY) Receivables - Other (2016 - 2025)

Eli Lilly's Receivables - Other history spans 14 years, with the latest figure at $2.4 billion for Q4 2025.

  • For Q4 2025, Receivables - Other rose 5.51% year-over-year to $2.4 billion; the TTM value through Dec 2025 reached $2.4 billion, up 5.51%, while the annual FY2025 figure was $2.4 billion, 5.51% up from the prior year.
  • Receivables - Other reached $2.4 billion in Q4 2025 per LLY's latest filing, down from $3.3 billion in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $3.3 billion in Q3 2025 to a low of $1.1 billion in Q1 2021.
  • Average Receivables - Other over 5 years is $1.9 billion, with a median of $1.7 billion recorded in 2022.
  • Peak YoY movement for Receivables - Other: dropped 20.02% in 2024, then surged 90.67% in 2025.
  • A 5-year view of Receivables - Other shows it stood at $1.5 billion in 2021, then rose by 14.34% to $1.7 billion in 2022, then surged by 35.05% to $2.2 billion in 2023, then increased by 1.08% to $2.3 billion in 2024, then rose by 5.51% to $2.4 billion in 2025.
  • Per Business Quant, the three most recent readings for LLY's Receivables - Other are $2.4 billion (Q4 2025), $3.3 billion (Q3 2025), and $3.0 billion (Q2 2025).